Moderate

REM sleep behaviour disorder

Dream enactment parasomnia · Neurology
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

A parasomnia with loss of normal REM atonia causing dream enactment with potentially injurious movements and vocalisations. Strongly predictive of future alpha-synuclein neurodegeneration (Parkinson's disease, dementia with Lewy bodies, MSA), with important counselling implications.

Red flags

  • Serious sleep-related injury to patient or bed partner
  • Emerging parkinsonism or cognitive decline
  • Features suggesting nocturnal seizures instead
  • Severe untreated obstructive sleep apnoea
  • Falls risk from clonazepam in elderly

Assessment

Differential diagnosis

  • Obstructive sleep apnoea with pseudo-RBD
  • Non-REM parasomnias (sleepwalking, night terrors)
  • Nocturnal seizures
  • Periodic limb movement disorder
  • Severe nightmares/PTSD
  • Medication-induced dream enactment

Investigations

  • Video-polysomnography confirming REM sleep without atonia
  • Collateral history of dream enactment and injury
  • Medication review (SSRIs/SNRIs can induce or unmask RBD)
  • Neurological examination for early parkinsonism/cognitive change
  • Consider dopaminergic imaging in research/specialist settings

Management

  • Take a collateral history of violent dream enactment and sleep-related injury
  • Exclude mimics, especially obstructive sleep apnoea and nocturnal seizures
  • Confirm with video-polysomnography showing REM without atonia
  • Review and rationalise antidepressants that may provoke it
  • Prioritise bedroom safety: remove sharp objects, pad surroundings, consider separate beds
  • Start melatonin as first-line pharmacotherapy
  • Use clonazepam where melatonin is insufficient, with caution in the elderly
  • Counsel sensitively about the risk of future neurodegenerative disease
  • Monitor longitudinally for emerging parkinsonism or cognitive decline
  • Offer support and research/trial opportunities where available

Drugs & doses

Melatonin 3-12 mg PO at bedtime (first-line, prolonged-release or immediate)
Clonazepam 0.25-0.5 mg PO nocte (caution in elderly, falls, cognitive impairment)
Review and reduce SSRIs/SNRIs where feasible
Avoid alcohol and sedatives that fragment sleep

Disposition

Specialist sleep/neurology service. Longitudinal monitoring for neurodegeneration. Safety counselling.

Complications & pitfalls

  • Injury to patient or bed partner
  • Progression to Parkinson's disease, DLB or MSA
  • Clonazepam sedation and falls
  • Relationship and sleep disruption
  • Psychological distress from prognosis

Exam pearls

  • RBD is a strong early marker of alpha-synuclein neurodegeneration; counsel carefully and sensitively
  • Bedroom safety is the single most important intervention
  • Melatonin is preferred first-line, especially in older or cognitively impaired patients
  • Antidepressants can induce or unmask RBD; review them

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.